The adjuvant administration of TAM reduced the recurrence of breast cancer and prolonged survival in women with operable breast cancer by 47% and the risk of death by 26% in patients with hormone-receptor-positive breast cancer [36]. The gene discussed is NR4A1; the disease is breast cancer.